Protera Positive Results from the Ongoing Phase 2 Bladder Cancer Trial

 

• TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures
• 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients
  
• 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients
  
• 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures
  
• Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events
  
• Company to host conference call and webcast today at 8:30 a.m. ET

Conference Call and Webcast

Protara will host a conference call and webcast to discuss the data today at 8:30 am ET. The live call can be accessed by registering as a participant here. Upon registration, participants will receive conference call dial-in information. A live webcast of the event can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

https://www.globenewswire.com/news-release/2024/12/05/2992222/0/en/Protara-Announces-Positive-Results-from-the-Ongoing-Phase-2-ADVANCED-2-Trial-of-TARA-002-in-Patients-with-NMIBC.html